Development and validation of the Canine Atopic Dermatitis Lesion Index, a scale for the rapid scoring of lesion severity in canine atopic dermatitis.

BACKGROUND The third iteration of the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) is the only tool rigorously validated for canine atopic dermatitis (CAD) lesion scoring. The CADESI-03 requires 248 evaluations, limiting its widespread use. HYPOTHESIS/OBJECTIVES The goal of the study was to develop and validate a practical method of grading CAD lesions that requires scoring only the frequently affected body regions. ANIMALS Fifty-seven privately owned atopic dogs were used in the study. METHODS The Canine Atopic Dermatitis Lesion Index (CADLI) was evaluated in an open, multicentre reliability study. Validity was assessed with expert opinion (content validity) and comparison of CADLI with existing disease severity measures (construct and criterion validity). Reliability was evaluated by analysing repeated observations of each dog. Convenience was assessed in terms of the time required to complete the scale. RESULTS The CADLI scores correlated with overall assessment scores (r = 0.60, P < 0.001, linear mixed model) and pruritus severity scores (r = 0.53, P < 0.001, linear mixed model), establishing construct validity. The CADLI was strongly correlated with CADESI-03 (r = 0.84, P < 0.001, linear mixed model), establishing criterion validity. The CADLI values obtained by two observers correlated very strongly (r = 0.91, P < 0.001), as did the repeat values for the same observer (r = 0.98, P < 0.001). The mean time to complete the CADLI was less than that required for CADESI-03 (1.9 and 12.6 min, respectively), a highly significant difference (P < 0.001). CONCLUSION AND CLINICAL IMPORTANCE The CADLI was found to be an effective measure of CAD lesion severity, strongly correlating with CADESI-03. The convenience of CADLI makes it suitable for use in both clinical research and practice.

[1]  J. Berry,et al.  Prednisolone therapy for atopic dermatitis is less effective in dogs with lower pretreatment serum 25-hydroxyvitamin D concentrations. , 2012, Veterinary dermatology.

[2]  P. Dubreuil,et al.  Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. , 2011, Veterinary dermatology.

[3]  R. Mueller,et al.  The influence of topical unsaturated fatty acids and essential oils on normal and atopic dogs. , 2011, Journal of the American Animal Hospital Association.

[4]  R. Marsella.  Tolerability and clinical efficacy of oral immunotherapy with house dust mites in a model of canine atopic dermatitis: a pilot study. , 2010, Veterinary dermatology.

[5]  J. Rybnicek,et al.  Correlation between pruritus score and grossly visible erythema in dogs. , 2010, Veterinary dermatology.

[6]  R. Mueller,et al.  Development of a questionnaire to assess the impact of atopic dermatitis on health-related quality of life of affected dogs and their owners. , 2010, Veterinary dermatology.

[7]  N. McEwan,et al.  The glucocorticoid sparing efficacy of Phytopica in the management of canine atopic dermatitis. , 2010, Veterinary dermatology.

[8]  C. Favrot,et al.  A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. , 2010, Veterinary dermatology.

[9]  D. Shaw,et al.  Tepoxalin reduces pruritus and modified CADESI-01 scores in dogs with atopic dermatitis: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. , 2009, Veterinary dermatology.

[10]  R. Mueller,et al.  The efficacy of commercially available veterinary diets recommended for dogs with atopic dermatitis. , 2008, Veterinary dermatology.

[11]  T. Olivry,et al.  Determination of CADESI-03 thresholds for increasing severity levels of canine atopic dermatitis. , 2008, Veterinary dermatology.

[12]  J. Rybnicek,et al.  Development of an owner-assessed scale to measure the severity of pruritus in dogs. , 2007, Veterinary dermatology.

[13]  T. Olivry,et al.  Validation of CADESI-03, a severity scale for clinical trials enrolling dogs with atopic dermatitis. , 2007, Veterinary dermatology.

[14]  R. Halliwell.  Revised nomenclature for veterinary allergy. , 2006, Veterinary immunology and immunopathology.

[15]  A. Hasegawa,et al.  A randomized comparative clinical trial of recombinant canine interferon-gamma (KT-100) in atopic dogs using antihistamine as control. , 2006, Veterinary dermatology.

[16]  R. Mueller,et al.  Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis , 2006, Veterinary Record.

[17]  E. Bensignor,et al.  CADESI (Canine Atopic Dermatitis Extent and Severity Index) reproducibility , 2005 .

[18]  W. Seewald,et al.  Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. , 2005, Journal of the American Veterinary Medical Association.

[19]  D. Shaw,et al.  Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a prospective, double-blinded, clinical study. , 2005, Veterinary dermatology.

[20]  L. Cronbach,et al.  My Current Thoughts on Coefficient Alpha and Successor Procedures , 2004 .

[21]  "Objective" measures of atopic dermatitis severity: in search of the holy Grail. , 2003, Archives of dermatology.

[22]  T. Olivry,et al.  A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: effects on dermal cellularity and cutaneous tumour necrosis factor-alpha. , 2003, Veterinary dermatology.

[23]  T. Olivry,et al.  Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. , 2002, Veterinary dermatology.

[24]  P. Kass,et al.  Canine atopic dermatitis: a retrospective study of 169 cases examined at the University of California, Davis, 1992-1998. Part II. Response to hyposensitization. , 2002, Veterinary dermatology.

[25]  S. Torres,et al.  A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of a Chinese herbal product (P07P) for the treatment of canine atopic dermatitis. , 2001, Veterinary dermatology.

[26]  D. DeBoer,et al.  The ACVD task force on canine atopic dermatitis (XV): fundamental concepts in clinical diagnosis. , 2001, Veterinary immunology and immunopathology.

[27]  H. Williams,et al.  Outcome measures of disease severity in atopic eczema. , 2000, Archives of dermatology.

[28]  T. Olivry,et al.  Treatment of canine atopic dermatitis with misoprostol, a prostaglandin E1 analogue: an open study , 1997 .

[29]  J. M. Cortina,et al.  What Is Coefficient Alpha? An Examination of Theory and Applications , 1993 .